Related Articles
Predictive factors in patients with EGFR mutation‑negative non‑small cell lung cancer treated with erlotinib
Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group
Erlotinib as second‑ or third‑line treatment in elderly patients with advanced non‑small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene